

Roblitinib

ALTERNATE NAMES:	FGF401; N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1- yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide; N-(5-cyano-4-((2- methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8- naphthyridine-1(2H)-carboxamide
CATALOG #:	B3008-1 1 mg B3008-5 5 mg
STRUCTURE:	
MOLECULAR FORMULA:	$C_{25}H_{30}N_8O_4$
MOLECULAR WEIGHT:	506.6
CAS NUMBER:	1708971-55-4
APPEARANCE:	Pale-yellow Solid
PURITY:	>98%
SOLUBILITY:	~5 mg/ml in DMSO (gently warm and vortex)
DESCRIPTION:	Roblitinib is a reversible-covalent inhibitor of fibroblast growth factor receptor 4 (FGFR4) tyrosine kinase. It shows 1000-fold selectivity for FGFR4 over FGFR1/2/3 and other kinases, with an IC_{50} value of 1.9 nM against FGFR4. It shows potent antitumor activity in mice bearing Hepatocellular carcinoma (HCC) tumor xenografts and patient-derived tumor xenograft PDX models. It has entered phase I/II clinical trials to evaluate its safety and efficacy in HCC and other solid tumors. It leads to upregulation of bile acid synthesis and a subsequent increase in ALT expression in preclinical studies, which can be prevented by combination with the bile acid sequestrant cholestyramine.
STORAGE TEMPERATURE:	-20°C. Store in the dark. Product is light sensitive. Protect from air. Store under desiccating conditions.
HANDLING:	Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
REFERENCE:	Lu, X., Chen, H., Patterson, A.V., et al. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects. J Med Chem. 62(6):2905-2915 (2019).
RELATED PRODUCTS: Theliatinib (Cat. No. B3004) Zanubrutinib (Cat. No. B2512) Savolitinib (Cat. No. B3006) Merestinib (Cat. No. B3007) Avitinib (Cat. No. B2995)	
DISCLAIMER:	FOR RESEARCH USE ONLY! Not to be used on humans.

03/20